Ma Qiu-Ping, Xu Er-Jiao, Zeng Qing-Jing, Su Zhong-Zhen, Tan Lei, Chen Jia-Xin, Zheng Rong-Qin, Li Kai
Department of Ultrasound, Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hepatol Res. 2019 Jul;49(7):799-809. doi: 10.1111/hepr.13336. Epub 2019 May 11.
To retrospectively compare the treatment effect of intraprocedural computed tomography/magnetic resonance-contrast-enhanced ultrasound (CT/MR-CEUS) fusion imaging (FI) with that of conventional ultrasound (US) in the guidance and assessment of thermal ablation of hepatocellular carcinoma (HCC).
The FI group (112 patients with 129 HCC) was treated between April 2010 and December 2012, whereas the US group (83 patients with 90 HCC) was treated between January 2008 and March 2010. Either CT/MR-CEUS FI or US was used to guide puncture, provide immediate assessment, and guide supplementary ablation. Technical efficacy, cumulative local tumor progression rate (LTP), recurrence-free survival (RFS), and overall survival (OS) were evaluated and compared during follow-up. Technical success rate of CT/MR-CEUS FI was also recorded.
Technical efficacy was significantly higher in the FI group than in the US group (100% vs. 86.7%, P < 0.001). The 1-, 2-, 3-, 4-, 5-, and 6-year cumulative LTP rates in the FI group were significantly lower than in the US group (3.8%, 4.9%, 6.0%, 6.0%, 7.2%, and 7.2% vs. 16.9%, 20.1%, 25%, 25%, 25%, and 25%, respectively; P < 0.001); RFS and OS were significantly higher in the FI group than in the US group (P = 0.027 and P = 0.049, respectively). The technical success rate of FI was 85.3%.
Intraprocedural CT/MR-CEUS FI improved the treatment effect of thermal ablation of HCC by immediately assessing treatment response and guiding supplementary ablation relative to those resulting from the use of conventional US.
回顾性比较术中计算机断层扫描/磁共振-对比增强超声(CT/MR-CEUS)融合成像(FI)与传统超声(US)在肝细胞癌(HCC)热消融引导及评估中的治疗效果。
FI组(112例患者,129个HCC病灶)于2010年4月至2012年12月接受治疗,而US组(83例患者,90个HCC病灶)于2008年1月至2010年3月接受治疗。采用CT/MR-CEUS FI或US引导穿刺、进行即时评估并指导补充消融。随访期间评估并比较技术疗效、累积局部肿瘤进展率(LTP)、无复发生存率(RFS)和总生存率(OS)。记录CT/MR-CEUS FI的技术成功率。
FI组的技术疗效显著高于US组(100%对86.7%,P<0.001)。FI组1年、2年、3年、4年、5年和6年的累积LTP率显著低于US组(分别为3.8%、4.9%、6.0%、6.0%、7.2%和7.2%对16.9%、20.1%、25%、25%、25%和25%;P<0.001);FI组的RFS和OS显著高于US组(分别为P=0.027和P=0.049)。FI的技术成功率为85.3%。
相对于传统超声,术中CT/MR-CEUS FI通过即时评估治疗反应并指导补充消融,提高了HCC热消融的治疗效果。